BiotechTube

Pegcetacoplan

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Delayed Graft Function

Conditions

Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant

Trial Timeline

Feb 1, 2026 → Aug 1, 2028

NCT ID
NCT07020832

About Pegcetacoplan

Pegcetacoplan is a phase 3 stage product being developed by Apellis Pharmaceuticals for Delayed Graft Function. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07020832. Target conditions include Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant.

What happened to similar drugs?

3 of 3 similar drugs in Delayed Graft Function were approved

Approved (3) Terminated (0) Active (0)
✅azathioprine + sirolimusAstellas PharmaApproved
✅Lemborexant + PlaceboEisaiApproved
✅Desflurane + PropofolBaxterApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (14)

NCT IDPhaseStatus
NCT04729062Pre-clinicalCompleted
NCT07020832Phase 3Recruiting
NCT06161584Pre-clinicalActive
NCT05809531Phase 3Active
NCT05067127Phase 3Completed
NCT04572854Phase 2Active
NCT04901936Phase 2Recruiting
NCT03531255Phase 3Active
NCT03593200Phase 2Completed
NCT03465709Phase 1/2Terminated
NCT02588833Phase 1Completed
NCT02503332Phase 2Completed
NCT02264639Phase 1Completed
NCT02461771Phase 1Completed

Competing Products

8 competing products in Delayed Graft Function

See all competitors
ProductCompanyStageHype Score
azathioprine + sirolimusAstellas PharmaApproved
43
Lemborexant + PlaceboEisaiApproved
50
Belatacept + EverolimusBristol Myers SquibbPhase 1
21
Belatacept + Calcineurin InhibitorBristol Myers SquibbPhase 2
31
ARGX-117ArgenxPhase 2
36
BG9418 (interferon beta-1a)BiogenPre-clinical
23
Desflurane + PropofolBaxterApproved
40
TNX-2110 + TNX-2120 + TNX-2130 + CANDIN + DiluentTonix PharmaceuticalsPhase 1
11